Bibliographic Details
| Title: |
58 - TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent and sustained inhibition against the HER2–HER3 signaling while sparing EGFR activity, leading to a large therapeutic window. |
| Authors: |
Irie, H., Ito, K., Kataoka, Y., Fujioka, Y., Oguchi, K., Shimamura, T., Kawai, Y., Sagara, T., Shibata, Y., Araki, H., Haruma, T., Hashimoto, A., Matsuo, K., Utsugi, T., Iwasawa, Y. |
| Source: |
European Journal of Cancer. Dec2016 Supplement 1, Vol. 69, pS26-S26. 1p. |
| Database: |
Academic Search Ultimate |
